...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American journal of Chinese medicine >Differences in individual efficacy of two Sairei-to preparations (Sojyutu-Sairei-to and Byakujyutu-Sairei-to) on recurrent spontaneous abortions of autoimmune etiologies evaluated by antinuclear antibody and anticardiolipin antibody titers.
【24h】

Differences in individual efficacy of two Sairei-to preparations (Sojyutu-Sairei-to and Byakujyutu-Sairei-to) on recurrent spontaneous abortions of autoimmune etiologies evaluated by antinuclear antibody and anticardiolipin antibody titers.

机译：通过抗核抗体和抗心磷脂抗体效价评估两种Sairei-to制剂（Sojyutu-Sairei-to和Byakujyutu-Sairei-to）对自身免疫病因反复自然流产的个体功效的差异。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The differences in individual efficacy of two Sairei-to preparations (Sojyutu-Sairei-to and Byakujyutu-Sairei-to) on antinuclear antibody (ANA) and anticardiolipin antibody (ACLA) positive recurrent spontaneous abortion (RSA) was analyzed in 52 patients (a total of 61 treatment sessions). Patients who failed to respond to initial treatment with Sojyutu-Sairei-to were additionally treated with Byakujyutu- Sairei-to, and the time course of ANA and ACLA titers in these patients was analyzed. ACLA titers were decreased significantly by the treatment of Byakujyutu-Sairei-to, however, the percentage of successfully prevented abortion cases did not differ significantly between the Sojyutu-Sairei-to treatment group and the Byakujyutu-Sairei-to treatment group. ACLA titer was decreased in all 10 cases where abortion was successfully prevented by the treatment with Sojyutu-Sairei-to or Byakujyutu-Sairei-to. In the cases where both ANA and ACLA were decreased following treatment with Sojyutu-Sairei-to or Byakujyutu-Sairei-to, the percentage of cases rated as "Kyo" and "Rikan" were significantly higher in the Byakujyutu-Sairei-to group. These results indicate that Byakujyutu-Sairei-to is effective against ACLA positive RSA through the antibody-reducing activity, which differs from that of Sojyutu-Sairei-to in individual cases. On the basis of these results, Sairei-to therapy, which is superior to aspirin and heparin in terms of efficacy and safety, is recommended as the first-line therapy for RSA of autoimmune etiologies. Furthermore, to elevate the percentage of successfully prevented abortions, it is advisable to select one of the two Sairei-to preparations (Sojyutu-Sairei-to and Byakujyutu-Sairei-to) on the basis of differential diagnosis using the methods of Oriental medicine.
机译：在52例患者中分析了两种Sairei-to制剂（Sojyutu-Sairei-to和Byakujyutu-Sairei-to）对抗核抗体（ANA）和抗心磷脂抗体（ACLA）阳性反复自然流产（RSA）的个体疗效差异。总共61个疗程）。对Sojyutu-Sairei-to的初始治疗无效的患者，再用Byakujyutu-Sairei-to进行治疗，并分析这些患者的ANA和ACLA滴度的时程。通过Byakujyutu-Sairei-to治疗，ACLA滴度显着降低，但是，成功的预防流产病例的百分比在Sojyutu-Sairei-to治疗组和Byakujyutu-Sairei-to治疗组之间没有显着差异。通过Sojyutu-Sairei-to或Byakujyutu-Sairei-to治疗成功预防流产的所有10例ACLA滴度均降低。在用Sojyutu-Sairei-to或Byakujyutu-Sairei-to治疗后ANA和ACLA均降低的情况下，Byakujyutu-Sairei-to组被评定为“ Kyo”和“ Rikan”的病例百分比显着更高。这些结果表明，Byakujyutu-Sairei-to通过降低抗体的活性对ACLA阳性RSA有效，这与个别情况下的Sojyutu-Sairei-to有所不同。根据这些结果，建议将Sairei-to治疗作为自身免疫病因RSA的一线治疗，在疗效和安全性方面均优于阿司匹林和肝素。此外，为了提高成功预防流产的比例，建议在使用东方医学方法进行鉴别诊断的基础上，选择两种Sairei-to制剂（Sojyutu-Sairei-to和Byakujyutu-Sairei-to）之一。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号